{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:14:43Z","timestamp":1723158883102},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,21]]},"DOI":"10.7759\/cureus.20588","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T06:50:15Z","timestamp":1640155815000},"source":"Crossref","is-referenced-by-count":0,"title":["The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib"],"prefix":"10.7759","author":[{"given":"Hassan","family":"Salame","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remy","family":"Mckey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Ballout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajih","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels EA","year":"2003","unstructured":"Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003, 105:546-51. 10.1002\/ijc.11099","journal-title":"Int J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels EA","year":"2010","unstructured":"Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 2010, 5:S260-5. 10.1097\/JTO.0b013e3181f1f62d","journal-title":"J Thorac Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.01.012","article-title":"Thymoma and thymic carcinomas","volume":"99","author":"Scorsetti M","year":"2016","unstructured":"Scorsetti M, Leo F, Trama A, et al.. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016, 99:332-50. 10.1016\/j.critrevonc.2016.01.012","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al.. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21:271-82. 10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol"},{"key":"ref5","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ROZLYTREK NDA 212725\/Orig1s000 approval letter. (2019). Accessed. July 28, 2021: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/212725Orig1s000ltr.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000154","article-title":"ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting","volume":"9","author":"Marx A","year":"2014","unstructured":"Marx A, Str\u00f6bel P, Badve SS, et al.. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014, 9:596-611. 10.1097\/JTO.0000000000000154","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx A","year":"2010","unstructured":"Marx A, Willcox N, Leite MI, Chuang WY, Schalke B, Nix W, Str\u00f6bel P. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. 2010, 43:413-27. 10.3109\/08916930903555935","journal-title":"Autoimmunity"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31821e7b12","article-title":"A review of prognostic factors in thymic malignancies","volume":"6","author":"Detterbeck F","year":"2011","unstructured":"Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol. 2011, 6:S1698-704. 10.1097\/JTO.0b013e31821e7b12","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard N","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015, 26:v40-55. 10.1093\/annonc\/mdv277","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone G","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, et al.. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018, 19:347-55. 10.1016\/S1470-2045(18)30062-7","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas A","year":"2015","unstructured":"Thomas A, Rajan A, Berman A, et al.. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015, 16:177-86. 10.1016\/S1470-2045(14)71181-7","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho J","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, et al.. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019, 37:2162-70. 10.1200\/JCO.2017.77.3184","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott LJ","year":"2019","unstructured":"Scott LJ. Larotrectinib: first global approval. Drugs. 2019, 79:201-6. 10.1007\/s40265-018-1044-x","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/69378-the-first-reported-case-of-neurotrophic-tyrosine-receptor-kinase-fusion-positive-thymoma-treated-successfully-with-entrectinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:41Z","timestamp":1707507281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/69378-the-first-reported-case-of-neurotrophic-tyrosine-receptor-kinase-fusion-positive-thymoma-treated-successfully-with-entrectinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.20588","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}